Table 1.

Patients baseline characteristics.

Variable	Whole sample
Median age (range)	65 (33−88)
Menopausal status
Pre-menopausal	23 (11%)
Post-menopausal	185 (89%)
Stage
I	102 (49%)
II	73 (35%)
III	33 (16%)
ER
⩽10%	16 (8%)
10−60%	23 (11%)
⩾60%	169 (81%)
AR
0	24 (12%)
⩽5%	11 (5%)
5−90%	112 (54%)
⩾90%	61 (29%)
Histotype
NOS/Ductal	131 (63%)
Lobular	67 (32%)
Other	10 (5%)
Grade
G1	18 (9%)
G2	130 (62%)
G3	60 (29%)
Ki67
<20%	148 (71%)
⩾20%	60 (29%)
Vascular invasion
Absent	83 (40%)
Mild	68 (33%)
Diffuse	13 (6%)
Not available	44 (21%)
Lymphoplasmacytic infiltrate
Low	149 (72%)
Moderate	13 (6%)
Not available	46 (22%)
Type of surgical intervention
Quadranctectomy + SLNB	86 (41%)
Quadrantectomy + ALND	58 (28%)
Mastectomy + SLNB	15 (7%)
Mastectomy + ALND	49 (24%)
Radiotherapy
Yes	141 (68%)
No	67 (32%)
Neoadjuvant therapy
No	171 (82%)
Yes	37 (18%)
Anthracycline	15 (41%)
Taxane	1 (3%)
Anthracycline + taxane	9 (24%)
Endocrine treatment	11 (30%)
Other (CMF)	1 (2%)
Adjuvant chemotherapy
No	142 (68%)
Yes	66 (32%)
Anthracycline	24 (36%)
Taxane	10 (15%)
Anthracycline + taxane	23 (35%)
Other	9 (14%)
Adjuvant endocrine therapy
No	20 (10%)
Yes	188 (90%)
Tamoxifen	19 (10%)
Aromatase inhibitors	150 (80%)
Tamoxifen + LHRH analogue	11 (6%)
Sequential	8 (4%)

ALND, axillary lymph node dissection; AR, androgen receptor; CMF, cyclophosphamide-methotrexate-fluorouracil; ER, estrogen receptor; LHRH, luteinizing hormone-releasing hormone; NOS, not otherwise specified; SLNB, sentinel lymph node biopsy; variable, analyzed variable; whole sample, variables’ distribution in the whole sample: median (25th−75th percentiles) or absolute and relative frequency (%).